A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia

Aurora kinase A is required for hematopoiesis but is dispensable for murine megakaryocyte endomitosis and differentiation

(2015) B. Goldenson et al.   BLOOD

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

(2015) K. M. Zullo et al.   CLINICAL CANCER RESEARCH

Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe

(2015) Jingjing Li et al.   Oncotarget

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

(2014) Antonino Maria Spartà et al.   CELL CYCLE

Aurora kinase inhibitor patents and agents in clinical testing: an update (2011 – 2013)

(2014) Chun Hei Antonio Cheung et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

(2012) Ursula A. Matulonis et al.   EUROPEAN JOURNAL OF CANCER

ENMD-2076 for hematological malignancies

(2012) Jonathan How et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process

(2010) L. Lordier et al.   BLOOD

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor,in Patients with Advanced Solid Tumors

(2010) J. R. Diamond et al.   CLINICAL CANCER RESEARCH

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

(2010) A S Moore et al.   LEUKEMIA

High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

(2010) Antonio R. Lucena-Araujo et al.   LEUKEMIA RESEARCH

ENMD-2076 Is an Orally Active Kinase Inhibitor with Antiangiogenic and Antiproliferative Mechanisms of Action

(2010) G. C. Fletcher et al.   MOLECULAR CANCER THERAPEUTICS

PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2

(2010) Yukiko Aikawa et al.   NATURE MEDICINE

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Aurora-A kinase: a novel target of cellular immunotherapy for leukemia

(2008) T. Ochi et al.   BLOOD

Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia

(2008) K. Kojima et al.   BLOOD

Aurora Kinases as Anticancer Drug Targets

(2008) O. Gautschi et al.   CLINICAL CANCER RESEARCH

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

(2008) E. Walsby et al.   HAEMATOLOGICA